A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Status:
Completed
Trial end date:
2016-01-25
Target enrollment:
Participant gender:
Summary
This is a Japanese Phase 1, open-label, and dose-escalating trial of TH-302 as monotherapy in
subjects with solid tumors and in combination with gemcitabine in subjects with pancreatic
cancer.